CHIRON |
Science
For Life
TRAFFIC Summary 3
Acceptable Safety Profile
Malignancy:
1 in placebo group
Hypotension
during dosing: < 6% (2, 4, 5)
Proteinuria:
< 5% (2, 6, 7)
Death + Cardiac SAEs (4, 4, 3)
Revascularizations (3, 2, 3)
Repeat administration after 30
days